Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 4/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | RBBP5 | Q15291 | 1/20 | 0.30 |
| ▸ | DPY30 | Q9C005 | 1/20 | 0.30 |
| ▸ | ASH2L | Q9UBL3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23137086 | 0.93 | — | — | |
| SCHEMBL23120386 | 0.91 | — | — | |
| SCHEMBL23137015 | 0.88 | NPEPPS (0.30) | — | |
| SCHEMBL23137075 | 0.87 | NPEPPS (0.30) | — | |
| SCHEMBL23120262 | 0.86 | NPEPPS (0.30) | — | |
| SCHEMBL23120257 | 0.86 | NPEPPS (0.30) | — | |
| SCHEMBL23137092 | 0.85 | KLK7 (0.32) | KMT2A | |
| SCHEMBL23120248 | 0.85 | NPEPPS (0.32) | — | |
| SCHEMBL23120243 | 0.85 | NPEPPS (0.32) | — | |
| SCHEMBL23120354 | 0.84 | NAPEPLD (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250332238-A1 | INHIBITION OF HISTONE METHYL TRANSFERASES TO TREAT CANCER | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2025-10-30 | — | — | US | disclosed |
| US-12357680-B2 | Inhibition of histone methyl transferases to treat cancer | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2025-07-15 | — | — | US | disclosed |
| US-20220184195-A1 | INHIBITION OF HISTONE METHYL TRANSFERASES TO TREAT CANCER | ALBERT-LUDWIGS-UNIVERSITAT FREIBURG (DE) | 2022-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220184195-A1 | INHIBITION OF HISTONE METHYL TRANSFERASES TO TREAT CANCER | KMT2A, KMT5A, DOT1L | NNMT 107/4885WDR5 357/4885KMT2A 1/4885 |
| US-20250332238-A1 | INHIBITION OF HISTONE METHYL TRANSFERASES TO TREAT CANCER | KMT2A, KMT5A, DOT1L | NNMT 107/4885WDR5 357/4885KMT2A 1/4885 |
| US-12357680-B2 | Inhibition of histone methyl transferases to treat cancer | KMT2A, KMT5A, DOT1L | NNMT 107/4885WDR5 357/4885KMT2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.